Menu
POTENTIAL DEAL DETAILS
| Stock | The Medicines Company | Symbol | MDCO |
| Date Announced | 11/19/2019 | Source | Bloomberg |
| Type | News Report |
| Date of Confirmation: | 11/24/2019 | Price at Confirmation: | $68.55 |
| Potential Profit: | -2.36% | Annualized Profit: | -172.60% |
Medicines Co. (MDCO), the developer of a promising cholesterol drug, has attracted takeover interest from suitors including Novartis AG (NVS), people familiar with the matter said.
Update(s):
November 24, 2019: Novartis AG (NVS) agreed to buy cholesterol-drugmaker Medicines Co. (MDCO)for nearly $10 billion, in a pricey bid to expand its reach in the lucrative market for heart treatments.
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.